Evidence map›Paper›PMID 40013135›Full record

ArticleFrontiers in immunology2025

Corrigendum: Distinction of early complement classical and lectin pathway activation

Lisa Hurler, Erik J M Toonen, Erika Kajdácsi, Bregje van Bree, Ricardo J M G E Brandwijk, Wieke de Bruin, Paul A Lyons, Laura Bergamaschi, Cambridge Institute of Therapeutic Immunology Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration, György Sinkovits and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Lisa HurlerDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Erik J M ToonenResearch and Development Department, Hycult Biotech, Uden, Netherlands.
Erika KajdácsiDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Bregje van BreeResearch and Development Department, Hycult Biotech, Uden, Netherlands.
Ricardo J M G E BrandwijkResearch and Development Department, Hycult Biotech, Uden, Netherlands.
Wieke de BruinResearch and Development Department, Hycult Biotech, Uden, Netherlands.
Paul A LyonsCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.
Laura BergamaschiCambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, United Kingdom.
Cambridge Institute of Therapeutic Immunology Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration
György SinkovitsDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
László CervenakDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Reinhard WürznerInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Zoltán ProhászkaDepartment of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.1039765.].

Indexed as

assay development and validationC1-INH complexesC1s/C1-INH complexclassical pathway activationearly complement activationlectin pathway activationMASP-1/C1-INH complex

Identifiers

PMID40013135
PMCPMC11862822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.